MDS Abstracts

Abstracts from the International Congress of Parkinson’s and Movement Disorders.

MENU 
  • Home
  • Meetings Archive
    • 2024 International Congress
    • 2023 International Congress
    • 2022 International Congress
    • MDS Virtual Congress 2021
    • MDS Virtual Congress 2020
    • 2019 International Congress
    • 2018 International Congress
    • 2017 International Congress
    • 2016 International Congress
  • Keyword Index
  • Resources
  • Advanced Search

History of Comorbidities and their Association with Developing Cognitive Dysfunction in PD

C. Venuto, K. Kieburtz, K. Herbst, G. Smith (Rochester, USA)

Meeting: 2022 International Congress

Abstract Number: 1261

Keywords: Cognitive dysfunction, Parkinson’s

Category: Parkinson's Disease: Cognitive functions

Objective: To examine comorbidities associated with incident cognitive dysfunction in PD.

Background: The risk of dementia is up to six-times higher in PD compared to those without PD of similar age. The degree to which additional comorbidities increase the risk of PD cognitive dysfunction merits investigation. Our objective was to evaluate the association of vascular and nonvascular comorbidity history with incident cognitive dysfunction among people recently diagnosed with PD at baseline.

Method: Cox proportional hazards regression was used to examine the association of comorbidity history with PD cognitive dysfunction. Longitudinal data came from a combined dataset of STEADY-PD III, and SURE-PD 3 clinical trials, and the Parkinson’s Progression Marker Initiative observational study. Cognitive dysfunction was defined as a score of <= 21 on the Montreal Cognitive Assessment (MoCA) scale. Comorbidity history was captured from the Medical History Forms focusing on select vascular conditions (angina, heart disease, transient ischemic attack, dyslipidemia, hypertension, and diabetes) and nonvascular conditions (depression, arthritis, asthma/chronic obstructive pulmonary disease, and cancer). Models were adjusted for sociodemographic factors (sex, education, age at baseline) and baseline MoCA.

Results: Among the 870 PD participants with normal cognition (MoCA >= 26) at baseline, 57 (7%) developed cognitive dysfunction (MoCA <=21) over an average (SD) follow-up time of 3.8 (2.2) years.  When considering only vascular comorbidities, those with >= 2 vascular comorbidities were at increased risk of progression to cognitive dysfunction (hazard ratio (HR), 2.26 [95% CI 1.30 – 3.91]) compared to those with <= 1 vascular comorbidity. For nonvascular comorbidities, the risk was not significantly greater for those with >= 2 nonvascular comorbidities (HR, 1.18 [95% CI 0.59 – 2.36]) compared to those with <= 1. Considering both vascular and nonvascular comorbidities together, the risk was higher for those with >= 3 comorbidities (HR, 1.87 [95% CI 1.01 – 3.46]) but diminished for those with just >= 2 comorbidities (HR, 1.20 [95% CI 0.60 – 2.41]).

Conclusion: History of two or more comorbidities, particularly of vascular origin, is associated with higher hazard of developing cognitive dysfunction in PD.  Future analyses will incorporate additional comorbidity conditions and cognition endpoints.

To cite this abstract in AMA style:

C. Venuto, K. Kieburtz, K. Herbst, G. Smith. History of Comorbidities and their Association with Developing Cognitive Dysfunction in PD [abstract]. Mov Disord. 2022; 37 (suppl 2). https://www.mdsabstracts.org/abstract/history-of-comorbidities-and-their-association-with-developing-cognitive-dysfunction-in-pd/. Accessed June 15, 2025.
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2022 International Congress

MDS Abstracts - https://www.mdsabstracts.org/abstract/history-of-comorbidities-and-their-association-with-developing-cognitive-dysfunction-in-pd/

Most Viewed Abstracts

  • This Week
  • This Month
  • All Time
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • Life expectancy with and without Parkinson’s disease in the general population
  • What is the appropriate sleep position for Parkinson's disease patients with orthostatic hypotension in the morning?
  • Patients with Essential Tremor Live Longer than their Relatives
  • Increased Risks of Botulinum Toxin Injection in Patients with Hypermobility Ehlers Danlos Syndrome: A Case Series
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • What is the appropriate sleep position for Parkinson's disease patients with orthostatic hypotension in the morning?
  • Life expectancy with and without Parkinson’s disease in the general population
  • The hardest symptoms that bother patients with Parkinson's disease
  • An Apparent Cluster of Parkinson's Disease (PD) in a Golf Community
  • Effect of marijuana on Essential Tremor: A case report
  • Increased Risks of Botulinum Toxin Injection in Patients with Hypermobility Ehlers Danlos Syndrome: A Case Series
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • Estimation of the 2020 Global Population of Parkinson’s Disease (PD)
  • Patients with Essential Tremor Live Longer than their Relatives
  • Help & Support
  • About Us
  • Cookies & Privacy
  • Wiley Job Network
  • Terms & Conditions
  • Advertisers & Agents
Copyright © 2025 International Parkinson and Movement Disorder Society. All Rights Reserved.
Wiley